Patents by Inventor Georgia D Tomaras

Georgia D Tomaras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding human immunodeficiency virus type 1 (HIV-1) N-terminal deleted gp120 immunogens and methods of use
    Patent number: 11053285
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: July 6, 2021
    Assignees: Duke University, THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY, Children's Medical Center Corporation
    Inventors: Jerome Kim, Stephen Harrison, Barton F. Haynes, Georgia D. Tomaras, Nelson Michael
  • N-TERMINAL DELETED GP120 IMMUNOGENS
    Publication number: 20180305411
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.
    Type: Application
    Filed: June 27, 2018
    Publication date: October 25, 2018
    Inventors: Jerome KIM, Stephen HARRISON, Barton F. HAYNES, Georgia D. TOMARAS, Nelson MICHAEL
  • Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
    Patent number: 10040826
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: August 7, 2018
    Assignees: DUKE UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Jerome Kim, Stephen Harrison, Barton F. Haynes, Georgia D. Tomaras, Nelson Michael
  • HERPES SIMPLEX VIRUS
    Publication number: 20140302062
    Abstract: The present invention relates, in general to herpes simplex virus (HSV) and, particular, to antibodies that are specific for glycoprotein D (gD) of HSV. The invention also relates to prophylactic and therapeutic uses of such antibodies.
    Type: Application
    Filed: April 9, 2012
    Publication date: October 9, 2014
    Applicants: U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, DUKE UNIVERSITY
    Inventors: Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody, Georgia D. Tomaras, Jerome Kim, Nelson Michael
  • N-TERMINAL DELETED GP120 IMMUNOGENS
    Publication number: 20140248311
    Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same.
    Type: Application
    Filed: July 5, 2012
    Publication date: September 4, 2014
    Applicants: DUKE UNIVERSITY, U.S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Jerome Kim, Stephen Harrison, Barton F. Haynes, Georgia D. Tomaras, Nelson Michael
  • HIV-1 IGG3 RESPONSE IN ACUTE HIV-1
    Publication number: 20130217002
    Abstract: The present invention relates, in general, to HIV-1 and, in particular, to methods of detecting incident HIV-1 infection.
    Type: Application
    Filed: October 3, 2011
    Publication date: August 22, 2013
    Applicants: DUKE UNIVERSITY
    Inventors: Georgia D. Tomaras, Nicole L. Yates, Myron S. Cohen, Barton F. Haynes
  • Methods for identification of CDS8+ suppressor molecules
    Patent number: 7037645
    Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8+ cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: May 2, 2006
    Assignee: Duke University
    Inventors: Dani P. Bolognesi, Michael L Greenberg, Simon F Lacey, Georgia D Tomaras, Kent J. Weinhold
  • Suppressor of HIV replication and transcription
    Patent number: 6528308
    Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8+ cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: March 4, 2003
    Assignee: Duke University
    Inventors: Dani P. Bolognesi, Michael L. Greenberg, Simon F. Lacey, Georgia D. Tomaras, Kent J. Weinhold
  • Suppressor of HIV replication and transcription
    Publication number: 20020102538
    Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8+ cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.
    Type: Application
    Filed: February 6, 2002
    Publication date: August 1, 2002
    Applicant: Duke University
    Inventors: Dani P. Bolognesi, Michael L. Greenberg, Simon F. Lacey, Georgia D. Tomaras, Kent J. Weinhold